Target intelligence / Profile preview

Host cells susceptible to Dengue virus serotype 2 infection

Molecular classification
Other
01

Overview

Host cells susceptible to Dengue virus serotype 2 (DENV-2) infection primarily include cells of the myeloid lineage, such as monocytes, macrophages, and dendritic cells, which are considered the principal targets in vivo (PubMed: 11160744). These cells express various attachment factors and receptors, most notably DC-SIGN (CD209), heparan sulfate proteoglycans, and the mannose receptor, which facilitate viral entry via receptor-mediated endocytosis (PubMed: 12502850). Upon entry, the virus utilizes the host cell's endoplasmic reticulum and translation machinery to replicate its positive-sense RNA genome and assemble new virions (Nature Reviews Microbiology). The infection of these cells is a critical step in the pathogenesis of Dengue fever and its more severe forms, Dengue Hemorrhagic Fever and Dengue Shock Syndrome, which are characterized by a 'cytokine storm' and increased vascular permeability (NIH: StatPearls). Therapeutic interventions targeting these cells often involve small molecule inhibitors of viral proteins like the NS5 polymerase or host-targeted agents like alpha-glucosidase inhibitors (e.g., Celgosivir) that prevent proper viral protein folding (PubMed: 24501055). A significant challenge in treating these cells is the risk of antibody-dependent enhancement (ADE), where non-neutralizing antibodies facilitate viral entry into Fc-receptor-bearing cells, potentially worsening the infection (Wikipedia). Additionally, hepatocytes and endothelial cells can also be infected, contributing to liver dysfunction and vascular leakage (Journal of Virology).

Other names
DENV-2 target cellsDengue virus serotype 2 susceptible cellsDENV-2 host cellsDENV-2 infected cells
02

Mechanism of action

Drugs targeting this system typically function by inhibiting viral enzymes (e.g., NS5 polymerase, NS3 protease) within the host cell, blocking viral entry via host receptors like DC-SIGN, or modulating host pathways such as alpha-glucosidase-mediated protein folding (PubMed: 24501055, 12502850).

03

Biological functions

Viral entryViral replicationImmune responseInflammatory responseCytokine production
04

Disease associations

InfectionDengue feverDengue hemorrhagic feverDengue shock syndrome
05

Safety considerations

Antibody-dependent enhancement (ADE)Cytotoxicity to essential immune cellsOff-target effects on host metabolic pathwaysSystemic inflammatory response syndrome
06

Interacting drugs

Balapiravir

4 more in the full profile.

07

Biomarkers

Dengue virus NS1 antigenViremia (DENV-2 RNA levels)Platelet countHematocrit levelsInterleukin-6 (IL-6)Tumor necrosis factor-alpha (TNF-alpha)

Beyond the preview

Go deeper on Host cells susceptible to Dengue virus serotype 2 infection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Host cells susceptible to Dengue virus serotype 2 infection.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call